These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 7769703)

  • 41. Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.
    Lusso P; Earl PL; Sironi F; Santoro F; Ripamonti C; Scarlatti G; Longhi R; Berger EA; Burastero SE
    J Virol; 2005 Jun; 79(11):6957-68. PubMed ID: 15890935
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Contribution of intrinsic reactivity of the HIV-1 envelope glycoproteins to CD4-independent infection and global inhibitor sensitivity.
    Haim H; Strack B; Kassa A; Madani N; Wang L; Courter JR; Princiotto A; McGee K; Pacheco B; Seaman MS; Smith AB; Sodroski J
    PLoS Pathog; 2011 Jun; 7(6):e1002101. PubMed ID: 21731494
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Synergistic neutralization of human immunodeficiency virus type 1 by a chimpanzee monoclonal antibody against the V2 domain of gp120 in combination with monoclonal antibodies against the V3 loop and the CD4-binding site.
    Vijh-Warrier S; Pinter A; Honnen WJ; Tilley SA
    J Virol; 1996 Jul; 70(7):4466-73. PubMed ID: 8676471
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Characterization of sera from subjects infected with HIV-1 subtypes B and E in Thailand by antibody binding and neutralization.
    Louisirirotchanakul S; Beddows S; Cheingsong-Popov R; Shaffer N; Mastro TD; Auewarakul P; Likanonsakul S; Wasi C; Weber J
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Dec; 19(4):315-20. PubMed ID: 9833739
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Differential CD4/CCR5 utilization, gp120 conformation, and neutralization sensitivity between envelopes from a microglia-adapted human immunodeficiency virus type 1 and its parental isolate.
    Martín J; LaBranche CC; González-Scarano F
    J Virol; 2001 Apr; 75(8):3568-80. PubMed ID: 11264346
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Adaptation to persistent growth in the H9 cell line renders a primary isolate of human immunodeficiency virus type 1 sensitive to neutralization by vaccine sera.
    Wrin T; Loh TP; Vennari JC; Schuitemaker H; Nunberg JH
    J Virol; 1995 Jan; 69(1):39-48. PubMed ID: 7983734
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Relationships between CD4 independence, neutralization sensitivity, and exposure of a CD4-induced epitope in a human immunodeficiency virus type 1 envelope protein.
    Edwards TG; Hoffman TL; Baribaud F; Wyss S; LaBranche CC; Romano J; Adkinson J; Sharron M; Hoxie JA; Doms RW
    J Virol; 2001 Jun; 75(11):5230-9. PubMed ID: 11333905
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Stable exposure of the coreceptor-binding site in a CD4-independent HIV-1 envelope protein.
    Hoffman TL; LaBranche CC; Zhang W; Canziani G; Robinson J; Chaiken I; Hoxie JA; Doms RW
    Proc Natl Acad Sci U S A; 1999 May; 96(11):6359-64. PubMed ID: 10339592
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Phenotypic Correlates of HIV-1 Macrophage Tropism.
    Arrildt KT; LaBranche CC; Joseph SB; Dukhovlinova EN; Graham WD; Ping LH; Schnell G; Sturdevant CB; Kincer LP; Mallewa M; Heyderman RS; Rie AV; Cohen MS; Spudich S; Price RW; Montefiori DC; Swanstrom R
    J Virol; 2015 Nov; 89(22):11294-311. PubMed ID: 26339058
    [TBL] [Abstract][Full Text] [Related]  

  • 50. HIV-1 R5 Macrophage-Tropic Envelope Glycoprotein Trimers Bind CD4 with High Affinity, while the CD4 Binding Site on Non-macrophage-tropic, T-Tropic R5 Envelopes Is Occluded.
    Quitadamo B; Peters PJ; Repik A; O'Connell O; Mou Z; Koch M; Somasundaran M; Brody R; Luzuriaga K; Wallace A; Wang S; Lu S; McCauley S; Luban J; Duenas-Decamp M; Gonzalez-Perez MP; Clapham PR
    J Virol; 2018 Jan; 92(2):. PubMed ID: 29118121
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Strain specificity and binding affinity requirements of neutralizing monoclonal antibodies to the C4 domain of gp120 from human immunodeficiency virus type 1.
    Nakamura GR; Byrn R; Wilkes DM; Fox JA; Hobbs MR; Hastings R; Wessling HC; Norcross MA; Fendly BM; Berman PW
    J Virol; 1993 Oct; 67(10):6179-91. PubMed ID: 7690420
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Structural modulations of the envelope gp120 glycoprotein of human immunodeficiency virus type 1 upon oligomerization and differential V3 loop epitope exposure of isolates displaying distinct tropism upon virion-soluble receptor binding.
    Stamatatos L; Cheng-Mayer C
    J Virol; 1995 Oct; 69(10):6191-8. PubMed ID: 7545244
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cyanovirin-N binds to gp120 to interfere with CD4-dependent human immunodeficiency virus type 1 virion binding, fusion, and infectivity but does not affect the CD4 binding site on gp120 or soluble CD4-induced conformational changes in gp120.
    Esser MT; Mori T; Mondor I; Sattentau QJ; Dey B; Berger EA; Boyd MR; Lifson JD
    J Virol; 1999 May; 73(5):4360-71. PubMed ID: 10196334
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Enhanced HIV infectivity and changes in GP120 conformation associated with viral incorporation of human leucocyte antigen class I molecules.
    Cosma A; Blanc D; Braun J; Quillent C; Barassi C; Moog C; Klasen S; Spire B; Scarlatti G; Pesenti E; Siccardi AG; Beretta A
    AIDS; 1999 Oct; 13(15):2033-42. PubMed ID: 10546855
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Enhancement of human immunodeficiency virus type 1 envelope-mediated fusion by a CD4-gp120 complex-specific monoclonal antibody.
    Lee S; Peden K; Dimitrov DS; Broder CC; Manischewitz J; Denisova G; Gershoni JM; Golding H
    J Virol; 1997 Aug; 71(8):6037-43. PubMed ID: 9223495
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A global neutralization resistance phenotype of human immunodeficiency virus type 1 is determined by distinct mechanisms mediating enhanced infectivity and conformational change of the envelope complex.
    Park EJ; Gorny MK; Zolla-Pazner S; Quinnan GV
    J Virol; 2000 May; 74(9):4183-91. PubMed ID: 10756031
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Resistance of primary isolates of human immunodeficiency virus type 1 to neutralization by soluble CD4 is not due to lower affinity with the viral envelope glycoprotein gp120.
    Turner S; Tizard R; DeMarinis J; Pepinsky RB; Zullo J; Schooley R; Fisher R
    Proc Natl Acad Sci U S A; 1992 Feb; 89(4):1335-9. PubMed ID: 1741386
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Inhibition of virus attachment to CD4+ target cells is a major mechanism of T cell line-adapted HIV-1 neutralization.
    Ugolini S; Mondor I; Parren PW; Burton DR; Tilley SA; Klasse PJ; Sattentau QJ
    J Exp Med; 1997 Oct; 186(8):1287-98. PubMed ID: 9334368
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Envelope proteins from clinical isolates of human immunodeficiency virus type 1 that are refractory to neutralization by soluble CD4 possess high affinity for the CD4 receptor.
    Brighty DW; Rosenberg M; Chen IS; Ivey-Hoyle M
    Proc Natl Acad Sci U S A; 1991 Sep; 88(17):7802-5. PubMed ID: 1909031
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Functional and immunologic characterization of human immunodeficiency virus type 1 envelope glycoproteins containing deletions of the major variable regions.
    Wyatt R; Sullivan N; Thali M; Repke H; Ho D; Robinson J; Posner M; Sodroski J
    J Virol; 1993 Aug; 67(8):4557-65. PubMed ID: 8331723
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.